|
(Health-NewsWire.Net, October 24, 2019 ) Market Overview
Opioid-induced constipation (OIC) is a type of secondary illness associated with prolonged use of opioids. Approximately 40%-80% of patients receiving opioid analgesic may experience OIC.
Market Dynamics
The market is primarily driven by an expanding the base of OIC sufferers as a result of increased use of opioids in the treatment of chronic pain.
The global burden of chronic pain is significant and growing with over 1.5 billion people suffering from it. However, lack of awareness about opioid-induced constipation in patients is likely to limit the market growth.
Also, there is a vast unmet need in the market for highly-targeted, safe and efficient therapeutic options for OIC management.
Traditional first-line approaches to treating OIC such as laxatives have limited efficacy. OIC can be chronic and may be unresponsive to common laxative treatment regimens.
Market Segmentation
Opioid-Induced Constipation Treatment market report segments the market by drug class, by the method of administration, by distribution channel, and by region.
Based on drug class, the OIC treatment market is categorized into Mu- Opioid Receptor Antagonist, Locally Acting Chloride Channel Activator, Peripherally-Restricted Mu-opioid Receptor Antagonist, and Non-selective Opioid Antagonist.
Mu-opioid Receptor Antagonists segment is likely to overtake chloride channel activators by 2025 regarding market share and revenue generation due to its higher efficacy compared to other drugs.
Based on the mode of administration, the market is segmented into oral and parenteral.
Based on the distribution channel, the market is segmented into a drug store, independent pharmacies, and hospital pharmacies.
Key Segments Covered in the report
By Drug Class
Mu-Opioid Receptor Antagonist
Locally Acting Chloride Channel Activator
Peripherally-Restricted Mu-opioid Receptor Antagonist
Non-selective Opioid Antagonist
By Mode of Administration
Oral
bowel movements
Parenteral
abdominal pain
By Distribution Channel
Hospital Pharmacies
Independent Pharmacies
Drug stores
Geographical Analysis
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
North America (The USA, Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Rest of the World
Company Profiles
The report also profiles the following companies in Opioid-Induced Constipation Treatment market GlaxoSmithKline, Inc., AstraZeneca plc, Inc., Pfizer, Inc., S.L.A. Pharma AG, AIKO Biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.
View full sample report: https://www.datamintelligence.com/research-report/opioid-induced-constipation-treatment-market
Download free sample: https://www.datamintelligence.com/download-sample/opioid-induced-constipation-treatment-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
